EMA Said PRAC Agreed To Add Atrial Fibrillation As Common Side Effect To Product Information For Medicines Containing Omega-3-acid Ethyl Esters
Portfolio Pulse from Charles Gross
The European Medicines Agency (EMA) has agreed to add atrial fibrillation as a common side effect to product information for medicines containing Omega-3-acid Ethyl Esters. This decision could potentially impact companies such as AMRN, AZN, EWU, and GSK, which may have such medicines in their portfolio.
September 29, 2023 | 11:43 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
AMRN, a company that may have medicines containing Omega-3-acid Ethyl Esters, could be impacted by EMA's decision to add atrial fibrillation as a common side effect.
The EMA's decision to add atrial fibrillation as a common side effect to medicines containing Omega-3-acid Ethyl Esters could potentially lead to a decrease in sales for AMRN if they have such medicines in their portfolio. This could negatively impact their stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
AZN, a company that may have medicines containing Omega-3-acid Ethyl Esters, could be impacted by EMA's decision to add atrial fibrillation as a common side effect.
The EMA's decision to add atrial fibrillation as a common side effect to medicines containing Omega-3-acid Ethyl Esters could potentially lead to a decrease in sales for AZN if they have such medicines in their portfolio. This could negatively impact their stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75
NEGATIVE IMPACT
EWU, an ETF that may have exposure to companies with medicines containing Omega-3-acid Ethyl Esters, could be impacted by EMA's decision to add atrial fibrillation as a common side effect.
The EMA's decision could potentially lead to a decrease in the stock prices of companies within the EWU ETF that have medicines containing Omega-3-acid Ethyl Esters. This could negatively impact the ETF's performance in the short term.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEGATIVE IMPACT
GSK, a company that may have medicines containing Omega-3-acid Ethyl Esters, could be impacted by EMA's decision to add atrial fibrillation as a common side effect.
The EMA's decision to add atrial fibrillation as a common side effect to medicines containing Omega-3-acid Ethyl Esters could potentially lead to a decrease in sales for GSK if they have such medicines in their portfolio. This could negatively impact their stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 75